Pre-clinical studies indicate that losartan, an angiotensin II receptor type 1 antagonist, demonstrates potential in reducing cancer-associated fibroblast (CAF) activity due to its anti-fibrotic properties (64, 65). This evidence concerns the gene AGTR1 and cancer.